PDI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Perit Dial Int 17(2): 129-135 1997
© 1997 International Society for Peritoneal Dialysis
This Article
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bajo, M.
Right arrow Articles by Sanchez-Sicilia, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bajo, M.
Right arrow Articles by Sanchez-Sicilia, A.
Peritoneal Dialysis International, Vol 17, Issue 2, 129-135
Copyright © 1997 by International Society for Peritoneal Dialysis

Articles

Erythropoietin treatment decreases cardiovascular morbidity and mortality in CAPD patients

MA Bajo, R Selgas, MJ Castro, C Jimenez, MJ Fernandez-Reyes, G Del Peso, F De Alvaro, and AL Sanchez-Sicilia

Hospital Universitario La Paz, Madrid, Spain.

OBJECTIVE: To analyze the effects of recombinant human erythropoietin (rHuEPO) therapy on cardiovascular (CV) morbidity and mortality among continuous ambulatory peritoneal dialysis (CAPD) patients. DESIGN: Retrospective comparative study. SETTING: CAPD unit in a university hospital. PATIENTS: Forty-two patients on rHuEPO treatment for at least one year were compared with an rHuEPO nonuser group of 113 patients. Subcutaneous rHuEPO doses were adjusted to a hemoglobin objective level of 10.5-13.5 g/dL. Fifty-seven patients were considered as high cardiovascular risk (HCVR), 17 in the rHuEPO group and 40 in the rHuEPO nonuser group. Ninety-eight patients were classified as low cardiovascular risk (LCVR), 25 of whom were in the rHuEPO group. RESULTS: The incidence of cardiovascular morbidity was more frequent in the rHuEPO nonuser than in the rHuEPO user group (40% vs 22%) and in HCVR than in LCVR patients (59.6% vs 20.4%). By multiple logistic regression analysis, the best model to explain the development of cardiovascular morbidity comprises rHuEPO treatment, CV risk, and age. In the rHuEPO user group, HCVR and LCVR patients did not show significant differences in survival, while in the rHuEPO nonuser group, HCVR patients had a lower survival rate than LCVR patients (p = 0.0003). Cox proportional hazards model revealed that LCVR patients had an excellent prognosis compared with HCVR patients in the rHuEPO nonuser group, but this difference disappeared in the rHuEPO user group. CONCLUSION: These data show a beneficial effect of rHuEPO treatment on cardiovascular morbidity and mortality in CAPD patients, evidenced by the elimination of the correlation between prior cardiovascular risk and subsequent mortality.




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
W. Grzeszczak, W. Sulowicz, B. Rutkowski, A. F. de Vecchi, R. Scanziani, P.-Y. Durand, A. Bajo, V. Vargemezis, and on behalf of the European Collaborative Group
The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin {beta} in peritoneal dialysis patients with chronic renal anaemia
Nephrol. Dial. Transplant., May 1, 2005; 20(5): 936 - 944.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Multimed Inc. logo
Copyright © 1997 by Multimed Inc.